Obesity and Its Comorbidities: Prevention and Therapy 2026

A special issue of Obesities (ISSN 2673-4168).

Deadline for manuscript submissions: 30 June 2026 | Viewed by 727

Special Issue Editor


E-Mail Website
Guest Editor
Department of Internal Medicine, Ospedale Cav. R. Apicella—ASL Napoli 3 Sud, Via di Massa, 1, 80040 Pollena, NA, Italy
Interests: obesity biology and integrated physiology; clinical trials and investigations; epidemiology/genetics; nutritional medicine; clinical nutrition medicine; genetics and nutrition; nutritional epidemiology; pharmacology; adipogenesis; behavioral epidemiology; biophysics and lipid metabolism; exercise and human physiology; phenotyping; fat cell physiology; aging; metabolic syndrome; nutrition behavior; eating disorder; over weight; adipocyte cell biology; etiology; psychological and epidemiological aspects of obesity and related disorders; diabetes; obesity; food science and technology; global health; appetite; dietary surveys; macronutrients; micronutrients; malnutrition; weight control
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The prevalence of overweight (body mass index3 25) and obesity (body mass index3 30) has reached epidemic proportions in most of the developed world. Obesity increases the risk for several co-morbidities, including type 2 diabetes (T2DM), stroke, cardiovascular disease (CVD), liver diseases, kidney diseases, and metabolic syndrome. The risks associated with obesity include various cancers such as prostate, breast, liver, kidney, colon, ovarian, and endometrial cancer.

Obesity contributes to increasing premature death worldwide. We invite authors to submit original research articles and reviews summarizing clinical, preclinical, or experimental results that analyze the role of prevention and therapy in the onset of obesity and its comorbidities. We are particularly interested in manuscripts that have relevance for T2DM, CVD, stroke, liver diseases, kidney diseases, metabolic syndrome, and cancers. Moreover, papers dealing with several factors linking the pathogenesis of obesity and related diseases are particularly welcome.

Dr. Carmine Finelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Obesities is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • type 2 diabetes (T2DM)
  • stroke
  • cardiovascular disease (CVD)
  • liver diseases
  • kidney diseases
  • metabolic syndrome
  • cancers prevention and therapy
  • obesity
  • overweight

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 230 KB  
Article
The Interplay of Diet, Lifestyle, and Metabolic Risk Among Saudi Adults with Metabolic Syndrome
by Maryam S. Hafiz, Wala I. Alzahrani, Sarah N. Alsharif, Doaa A. Alyoubi, Amal M. Alrizqi and Hanan Alwassam
Obesities 2025, 5(4), 91; https://doi.org/10.3390/obesities5040091 - 8 Dec 2025
Abstract
Metabolic syndrome (MetS) is a multifactorial condition characterized by central obesity, hypertension, dyslipidaemia, and hyperglycaemia, predisposing individuals to cardiovascular disease and type 2 diabetes. This cross-sectional study investigated the relationship between dietary intake, sociodemographic factors, and components of MetS among Saudi adults aged [...] Read more.
Metabolic syndrome (MetS) is a multifactorial condition characterized by central obesity, hypertension, dyslipidaemia, and hyperglycaemia, predisposing individuals to cardiovascular disease and type 2 diabetes. This cross-sectional study investigated the relationship between dietary intake, sociodemographic factors, and components of MetS among Saudi adults aged 30 years and older attending King Abdulaziz University Hospital. Fifty-three participants meeting MetS diagnostic criteria were assessed through anthropometric measurements, biochemical markers, and two-day dietary recalls analyzed using MyFood24 software. Descriptive and correlation analyses were conducted using SPSS 26.0. The majority of participants (73.6%) were aged over 50 years, were obese (75.5%), and exhibited a high waist circumference (94.3%). Low fibre (6.6 g/day) and high fat (41.8 g/day) intake patterns were evident. Salt intake showed a significant inverse correlation with systolic blood pressure (ρ = −0.36, p < 0.01), potentially reflecting under-reporting or dietary adjustments following diagnosis. Higher BMI correlated positively with waist circumference and diastolic pressure, while frequent physical activity correlated negatively with these parameters. These findings emphasize the influence of diet and lifestyle on metabolic risk and underscore the need for culturally tailored interventions promoting balanced macronutrient intake, increased fibre consumption, and enhanced physical activity to mitigate MetS prevalence among Saudi adults. Full article
(This article belongs to the Special Issue Obesity and Its Comorbidities: Prevention and Therapy 2026)
8 pages, 781 KB  
Article
Evaluating Dose Titration in Semaglutide and Tirzepatide for Weight Loss: A Retrospective Academic Call Center Study
by Goar Alvarez, Lianette Veliz, Stephanie Michaels, David Pino and Jun Wu
Obesities 2025, 5(4), 90; https://doi.org/10.3390/obesities5040090 - 5 Dec 2025
Viewed by 246
Abstract
Obesity affects approximately 40% of U.S. adults and is associated with increased cardiometabolic risk. While lifestyle interventions remain fundamental, pharmacologic therapies such as Semaglutide and tirzepatide have demonstrated significant weight reduction in clinical trials when titrated to maintenance doses. However, real-world adherence to [...] Read more.
Obesity affects approximately 40% of U.S. adults and is associated with increased cardiometabolic risk. While lifestyle interventions remain fundamental, pharmacologic therapies such as Semaglutide and tirzepatide have demonstrated significant weight reduction in clinical trials when titrated to maintenance doses. However, real-world adherence to recommended titration schedules remains unclear. This retrospective observational study evaluated adults prescribed Semaglutide (Wegovy®) or Tirzepatide (Zepbound®) for weight management between January 2021 and April 2025 through ICUBAcares, a pharmacist-led call center. Primary outcomes included the proportion of patients reaching the recommended maintenance dose and time required to do so. Secondary outcomes examined prescriber specialty patterns and monthly plan costs for non-optimized dosing. Among 739 medication courses, 52.9% of Semaglutide users reached the 2.4 mg dose versus 77.6% of tirzepatide users reaching 15 mg (p < 0.001). Median time to maintenance was significantly shorter for tirzepatide (32 days) than Semaglutide (143 days) (p < 0.001). Endocrinologists had the highest success rate for Tirzepatide (88.2%), while family medicine had the highest volume for both. Non-optimized dosing was associated with higher estimated monthly plan costs. These findings underscore the importance of improving adherence to titration protocols in real-world settings to maximize both clinical and economic outcomes in obesity pharmacotherapy. Full article
(This article belongs to the Special Issue Obesity and Its Comorbidities: Prevention and Therapy 2026)
Show Figures

Figure 1

Back to TopTop